ThinkEquity Starts Cubist Pharmaceuticals (CBST) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts CBST Hot Sheet
Price: $101.94 --0%
Rating Summary:
6 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 23 | Down: 26 | New: 23
Rating Summary:
6 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 23 | Down: 26 | New: 23
Join SI Premium – FREE
ThinkEquity initiates coverage on Cubist Pharmaceuticals (NASDAQ: CBST) with a Buy. PT $5.00.
For an analyst ratings summary and ratings history on Cubist Pharmaceuticals click here. For more ratings news on Cubist Pharmaceuticals click here.
Shares of Cubist Pharmaceuticals closed at $43.61 yesterday.
For an analyst ratings summary and ratings history on Cubist Pharmaceuticals click here. For more ratings news on Cubist Pharmaceuticals click here.
Shares of Cubist Pharmaceuticals closed at $43.61 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wedbush Starts Nuscale Power (SMR) at Underperform
- Wedbush Starts Terrestrial Energy Inc. (IMSR) at Neutral
- H.C. Wainwright Starts Teva Pharma (TEVA) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
ThinkEquitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
